In the past week, VRCA stock has gone up by 15.48%, with a monthly gain of 22.51% and a quarterly surge of 13.99%. The volatility ratio for the week is 4.25%, and the volatility levels for the last 30 days are 6.56% for Verrica Pharmaceuticals Inc The simple moving average for the past 20 days is 12.45% for VRCA’s stock, with a -27.38% simple moving average for the past 200 days.
Is It Worth Investing in Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Right Now?
VRCA has 36-month beta value of 1.77. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for VRCA is 50.08M, and currently, short sellers hold a 4.53% ratio of that float. The average trading volume of VRCA on June 13, 2025 was 382.35K shares.
VRCA) stock’s latest price update
The stock of Verrica Pharmaceuticals Inc (NASDAQ: VRCA) has increased by 8.15 when compared to last closing price of 0.62.Despite this, the company has seen a gain of 15.48% in its stock price over the last five trading days. globenewswire.com reported 2025-05-28 that WEST CHESTER, Pa., May 28, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference in New York City.
Analysts’ Opinion of VRCA
Needham gave a rating of “Buy” to VRCA, setting the target price at $10 in the report published on July 25th of the previous year.
VRCA Trading at 27.47% from the 50-Day Moving Average
After a stumble in the market that brought VRCA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.72% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRCA starting from Hayes Christopher G., who sale 4,315 shares at the price of $0.65 back on Mar 17 ’25. After this action, Hayes Christopher G. now owns 176,458 shares of Verrica Pharmaceuticals Inc, valued at $2,805 using the latest closing price.
Hayes Christopher G., the CHIEF LEGAL OFFICER of Verrica Pharmaceuticals Inc, sale 26,183 shares at $2.66 during a trade that took place back on Aug 26 ’24, which means that Hayes Christopher G. is holding 115,303 shares at $69,647 based on the most recent closing price.
Stock Fundamentals for VRCA
Current profitability levels for the company are sitting at:
- -7.72 for the present operating margin
- 0.72 for the gross margin
The net margin for Verrica Pharmaceuticals Inc stands at -9.19. The total capital return value is set at -4.34. Equity return is now at value -1546.58, with -121.65 for asset returns.
Based on Verrica Pharmaceuticals Inc (VRCA), the company’s capital structure generated -3.7 points at debt to capital in total, while cash flow to debt ratio is standing at -3.67. The debt to equity ratio resting at -0.79. The interest coverage ratio of the stock is -11.34.
Currently, EBITDA for the company is -65.9 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 6.6. The receivables turnover for the company is 1.28for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.34.
Conclusion
To put it simply, Verrica Pharmaceuticals Inc (VRCA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
